Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LY N001

Next Previous
Drug Profile

LY N001

Alternative Names: LY-N001

Latest Information Update: 10 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lingyi Biotech
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 07 Jul 2026 Lingyi Biotech plans a phase I trial for Parkinson's disease in China (intracerebral) in July 2026 (NCT07685444 )
  • 25 Jul 2025 Preclinical trials in Parkinson's disease in China (Parenteral) before July 2025 (Lingyi Biotech pipeline, July 2025)
  • 20 Dec 2023 Early research in Neurodegenerative disorders in China (Parenteral), prior to December 2023 (Lingyi Biotech pipeline, December 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top